AI
ACAD icon

Axecap Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Axecap Investments’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-152,910
Closed -$3.4M – 74
2026
Q1 		$3.4M Buy
152,910
+16,234
+12% +$388K 2.34% 17
2025
Q4 		$3.65M Sell
136,676
-66,695
-33% -$1.59M 2.25% 14
2025
Q3 		$4.34M Buy
+203,371
New +$4.81M 2.68% 12

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Axecap Investments's ACAD Position: Q2 2026 in Review

Axecap Investments sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 152,910 shares — an estimated $3.4M sold.

Axecap Investments first reported a position in ACAD in Q3 2025 and held it in 3 quarters. The position peaked at $4.34M in Q3 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Axecap Investments reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Axecap Investments sold 152,910 Acadia Pharmaceuticals shares in Q2 2026, an estimated $3.4M.
  • Axecap Investments first reported a position in Acadia Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Axecap Investments's Acadia Pharmaceuticals position peaked at $4.34M in Q3 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Axecap Investments's 13F filing for Q2 2026, filed 10 Aug 2026.